Small Cell Lung Cancer (SCLC)
NHS Scotland Cancer Collaborative: Clinical Management Pathways
Throughout the patient pathway, consideration should be given to patient eligibility and suitability for available clinical trials and discussed with individual patients as appropriate.
Patients with mixed SCLC/NSCLC pathology or those for concurrent chemoradiotherapy but with insufficient tissue sample for clear pathology, may be considered for carboplatin and etoposide.
| Author | Nicola Steele (on behalf of SACT subgroup) | Reviewer | John Maclay |
|
Date of creation Update |
20/09/2023 08/07/2026 |
Version number | 1.2 |
| Description of last update |
08/07/2026
Section: Limited Stage SCLC
Durvalumab added to pathway in line with SMC2818 advice. 23/07/2025
Section: Extensive Stage SCLC Durvalumab in combination with etoposide and carboplatin added following SMC2734 advice. Minor updates made to pathway for clarity around this change.
|
||
| Review Date | 20/09/2026 | Contact | nss.nscc@nhs.scot |
The printing of visual pathways is strongly discouraged, due to the inability to print all relevant information contained within and behind the pathways. Any user choosing to do so must acknowledge that the information may be incomplete and that essential context may be missing from a printed or reproduced pathway.